TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc. on May 26, 2022. The filing details the entry into a new material definitive credit agreement and the simultaneous termination of a prior credit agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance metrics such as revenue or profit, which are not provided in this document.
- New Debt Facility: Entered into a Credit and Security Agreement with MidCap Financial Trust for up to $50.0 million in term loans.
- Initial Borrowing: Borrowed $40.0 million (Tranche 1) upon closing.
- Future Borrowing: Eligible to borrow an additional $10.0 million (Tranche 2) upon meeting conditions, including reaching $65.0 million in net product revenue by fiscal year-end 2023.
- Interest Rate: 6.25% plus the greater of one-month Term SOFR or 1.0%.
- Maturity Date: May 1, 2027.
- Repayment Terms: 36 months of interest-only payments beginning June 1, 2022. Principal amortization depends on covenant compliance at the end of the interest-only period.
- Prepayment and Exit Fees: Prepayment fees range from 3.0% to 1.0% depending on the year of prepayment. A 5% exit fee is required at maturity or prepayment.
- Collateral: First priority security interest in all existing and future assets, including intellectual property.
Material Changes Versus Prior Period
The company terminated its Existing Credit Agreement with OrbiMed Royalty Opportunities II, LP. To effect this termination, the company paid the outstanding balance and fees, including prepayment expenses, totaling approximately $33.2 million using proceeds from the new facility.
Guidance, Risks, and Covenants
The new agreement imposes significant operational and financial restrictions on the company.
- Financial Covenants: The company must maintain minimum net revenue levels tested quarterly.
- Operational Restrictions: Covenants limit the ability to incur additional indebtedness, create liens, change management or business structure, merge or acquire other companies, pay dividends, repurchase stock, or make certain investments.
- Default Consequences: Events of default include non-payment, breach of covenants, and material adverse effects. Default triggers an interest rate penalty of 2% above the current rate.
- Use of Proceeds: Proceeds were used to repay the existing debt and fund operations and general corporate purposes.
Investor Verification Checklist
- Verify the company's current net product revenue trajectory against the $65.0 million threshold required to access Tranche 2 funding by fiscal year-end 2023.
- Review the specific quarterly minimum net revenue levels required to maintain covenant compliance.
- Assess the impact of the 5% exit fee and potential prepayment fees on future liquidity and refinancing options.
- Confirm the company's ability to service the interest-only payments starting June 1, 2022, given the interest rate structure (6.25% + SOFR/1.0%).
- Examine the restrictions on capital stock repurchases and dividends to understand limitations on shareholder returns.